Fig. 3
Elevated CYP2B6 m6A modification and upregulation of CYP2B6 expression were identified in NAFLD model. A mouse m6A epitranscriptomic microarray test of the NAFLD mice liver between HFD and control group, of all the mRNA detected, 108 hypermethylated and 212 hypomethylated genes were changed significantly in HFD-fed group (A). The GO and pathway analysis of the methylated mRNA showed metabolic process were enriched (B) and in Type II diabetes mellitus, insulin signaling pathway and adipocytokine signaling pathway (C). Between all the methylated mRNA, CYP450 family genes were plotted in the heatmap, the Merip-qPCR analysis showed Cyp2b10 (ENSMUST00000005477) m6A level was elevated (D) in the HFD group. IHC staining and quantitative analysis of Cyp2b10 in mice liver from HFD group and control group. Scale bars, 20 μm (E). A RT-qPCR analysis of Cyp2b6 between HFD group and control group and a western blot analysis of CYP2B6 (Homologous to mouse Cyp2b10 in HepG2. A western blot analysis of CYP2B6 in patients’ liver between the NAFLD group (n = 4) and the CD group (n = 4)